Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Vascular Solutions takes thrombus tech to Japan

This article was originally published in Clinica

Executive Summary

Vascular Solutions is to start selling in Japan its Pronto catheter, a device that uses mechanical aspiration to remove acute thrombus from the arterial system. The Minneapolis, Minnesota firm said it had received notification from its Japanese distributor Nihon Kohden that the import licence and reimbursement notification for the product's sale in Japan had been completed. "After the US...Japan is the second largest market for thrombus aspiration catheters," said Howard Root, Vascular Solutions' CEO. "Removal of acute thrombus is a potential $100m annual worldwide market opportunity that we are only beginning to realise with the Pronto as it enters its second year of commercial launch and expanding worldwide markets." Clinica FILED 1 June 2005 COPYRIGHT T&F Informa UK Ltd 2005

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT055316

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel